



## Food Microbiology

# Multidrug resistance and ESBL-producing *Salmonella* spp. isolated from broiler processing plants



Rosangela Estel Ziech<sup>a,\*</sup>, Camila Lampugnani<sup>a</sup>, Ana Paula Perin<sup>a</sup>,  
Mallu Jagnow Sereno<sup>a</sup>, Ricardo Antônio Pilegi Sfaiotte<sup>b</sup>, Cibeli Viana<sup>a</sup>,  
Vanessa Mendonça Soares<sup>c</sup>, José Paes de Almeida Nogueira Pinto<sup>c</sup>,  
Luciano dos Santos Bersot<sup>a</sup>

<sup>a</sup> Programa de Pós-Graduação em Ciência Animal, Universidade Federal do Paraná (UFPR), Rua Pioneiro n° 2153, Bairro Jardim Dallas, Palotina, PR 85950-000, Brazil

<sup>b</sup> Universidade Federal do Paraná (UFPR), Rua Pioneiro n° 2153, Bairro Jardim Dallas, Palotina, PR 85950-000, Brazil

<sup>c</sup> Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Medicina Veterinária e Zootecnia de Botucatu, Distrito de Rubião Júnior s/n, Botucatu SP18618-000, Brazil

## ARTICLE INFO

## Article history:

Received 16 December 2014

Accepted 24 July 2015

Associate Editor: Eduardo Cesar Tondo

## Keywords:

Antimicrobial resistance

*Salmonella* spp.

Food borne pathogens

## ABSTRACT

The aim of this study was to investigate the occurrence of multidrug-resistant, extended spectrum beta-lactamase (ESBL) producing *Salmonella* spp. isolated from conveyor belts of broiler cutting rooms in Brazilian broiler processing plants. Ninety-eight strains of *Salmonella* spp. were analyzed. Multidrug resistance was determined by the disk diffusion test and the susceptibility of the isolated bacteria was evaluated against 18 antimicrobials from seven different classes. The double disk diffusion test was used to evaluate ESBL production. Of the 98 strains tested, 84 were multidrug resistant. The highest rates of resistance were against nalidixic acid (95%), tetracycline (91%), and the beta-lactams: ampicillin and cefachlor (45%), followed by streptomycin and gentamicin with 19% and 15% of strain resistance, respectively. By contrast, 97% of the strains were sensitive to chloramphenicol. 45% of the strains were positive for the presence of ESBL activity. In this study, high rates of multidrug resistance and ESBL production were observed in *Salmonella* spp.

© 2015 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author.

E-mail: [reziech@gmail.com](mailto:reziech@gmail.com) (R.E. Ziech).

<http://dx.doi.org/10.1016/j.bjm.2015.11.021>

1517-8382/© 2015 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

*Salmonella* spp. is one of the main agents responsible for several infections, e.g., food borne gastroenteritis. Most of these infections cause self-limiting diarrhea and do not require antimicrobial treatment. However, in certain cases, such as when the bacterium is spread via blood stream leading to complications such as meningitis, antibiotic therapy is necessary. Such complications are most commonly observed in children and elderly and immune compromised patients. Fluoroquinolones and cephalosporins are the drugs of first-choice in such cases.<sup>1</sup>

Food of animal origin, especially poultry derived items, are the main sources of infection by *Salmonella* spp.<sup>2</sup> Given the importance to *Salmonella* spp. as causative agents in food borne diseases, reduction of its contamination on broiler carcasses is of extremely high priority for industry as well as regulatory agencies.<sup>3</sup> The occurrence of *Salmonella* spp. on the broiler carcasses might be a result of contamination either at the farm or cross-contamination within the processing plant.<sup>4</sup> Cross-contamination can be attributed partly to residual bacteria remaining on surfaces and equipment after sanitization.<sup>5</sup>

Studies on *Salmonella* spp. are usually focused on analyzing resistance of the bacterium to antimicrobials such as fluoroquinolones; but, in the last decade or so, bacterial production of large spectrum beta-lactamases has also been evaluated.<sup>6,7</sup> In Enterobacteriaceae, resistance to cephalosporins is generally attributed to the production of large spectrum beta-lactamases such as ESBL (extended spectrum beta-lactamase) and AmpC beta-lactamase.<sup>8</sup> ESBL is the term used for any beta-lactamase that is acquired and not intrinsic to a species. Such lactamases quickly hydrolyze and confer resistance against oxyimino-cephalosporins. Mutant beta-lactamases that have similar activity are also referred to as ESBLs.<sup>9,10</sup>

Extensive studies have been undertaken to analyze ESBL production by *Klebsiella* spp., *Enterobacter* spp., and *Escherichia coli* isolated from human clinical samples. These studies are prompted by the lack of therapeutic success against these microorganisms, which includes, but not restricted to, cephalosporins. Treatment is rendered unsuccessful by the acquisition of resistance genes that reside on mobile genetic elements. For example, plasmids that transmit resistance genes for cephalosporins are frequently found to carry resistance to other antibiotics, such as fluoroquinolones.<sup>11</sup> Some authors have also reported ESBLs in microorganisms isolated from food products.<sup>12-14</sup> According to Blanc et al. (2006), these findings are more recent in the case of *E. coli* and *Salmonella* spp. as compared to *Klebsiella* spp. and *Enterobacter* spp. ESBL production by *Salmonella* spp. isolated from animals has also been reported<sup>15,16</sup>; although, the reports on ESBL from animal origin are less frequent.<sup>17,18</sup>

Due to the public health risk of cross-contamination, it is important to have sufficient information on the occurrence of pathogens, e.g., *Salmonella* spp., in the cutting rooms for broiler processing and slaughtering facilities. It is especially important to have knowledge of the behavior of these strains against antimicrobials. Therefore, the objective of

this study was to determine the occurrence of multidrug resistant in ESBL-producing *Salmonella* spp. isolated from conveyor belts in the cutting rooms of broiler processing plants.

## Materials and methods

### Isolation and identification of *Salmonella* spp.

Strains of *Salmonella* spp. were obtained from the cutting rooms of four different Brazilian broiler processing and exporting plants having a slaughtering capacity in excess of 160,000 broilers/day. For the isolation of *Salmonella* spp. from the surface of the conveyor belts, the sponges (Nasco Whirl-Pak™), pre-moistened with 10 mL of 0.1% saline peptone water, were utilized on a 400 cm<sup>2</sup> area. *Salmonella* spp. detection was carried out according to the Food and Drug Administration (FDA – USA) methodology as published in the Bacteriological Analytical Manual.<sup>19</sup> Subsequent to these tests, isolates of *Salmonella* spp. were confirmed by genus identification using polymerase chain reaction (PCR) for the *sifB* gene as per the protocol described by Almeida et al.<sup>20</sup>

### Antimicrobial susceptibility test

The susceptibility to antimicrobials was determined using the agar diffusion test as per the documents M31-A3<sup>21</sup> and M100-S23<sup>22</sup> of the Clinical and Laboratory Standards Institute. Eighteen antimicrobial agents from seven different classes were tested: (1) Beta-lactams, divided into 3 subclasses: (a) Penicillins: ampicillin (AMP; 10 µg), (b) Cephalosporins: cefachlor (CFC; 30 µg) and ceftiofur (CTF; 30 µg), and (c) Carbapenems: meropenem (MER; 10 µg) and imipenem (IPM; 10 µg); (2) Aminoglycosides: streptomycin (EST; 10 µg), tobramycin (TOB; 10 µg), gentamycin (GEN; 10 µg), amikacin (AMI; 30 µg) and neomycin (NEO; 30 µg); (3) Quinolones: enrofloxacin (ENO; 5 µg), nalidixic acid (NAL; 30 µg), and ciprofloxacin (CIP; 5 µg); (4) Sulfamethoxazole and Trimethoprim: sulfamethoxazole/trimethoprim (SUT; 25 µg); (5) Tetracyclines: tetracycline (TET; 30 µg); (6) Phenicol: chloramphenicol (CLO; 30 µg) and florfenicol (FLF; 30 µg) and (7) Polymyxins: polymyxin B (POL, 300 UI). Strains were considered multidrug resistant if they were resistant to at least three classes of antimicrobials (at least one antimicrobial of each class).<sup>23</sup> The quality control test was based on *E. coli* ATCC 25922.

### ESBL production

ESBL production was analyzed by the double disk diffusion test.<sup>24</sup> The central disk was having amoxicillin plus clavulanic acid (AMX/AC; 20/10 µg). Four other disks were placed within a 20 mm radius of the first one: ceftazidime (CAZ; 30 µg), ceftriaxone (CRO; 30 µg), cefepime (CPM, 30 µg) and aztreonam (ATM; 30 µg).<sup>25</sup> Samples were considered positive for ESBL when the inhibition zone around any cephalosporin increased toward the central disk with AMX/AC, and when the inhibition zone around at least one of the cephalosporins was smaller than 19 mm.<sup>26</sup>

## Results

Out of the 98 strains evaluated (26, 23, 19, and 30 from each of the four cutting rooms, respectively), three were sensitive to all antimicrobials tested, four were resistant to one class, seven were resistant to two classes, and 84 (86%) were considered multidrug resistant.

Fig. 1 shows the resistance profiles of the multidrug resistant strains arranged according to the room of origin, and the corresponding percentage profiles in each room. ESBL activity was detected in 45% of the strains. From the strains positive for ESBL production, the most frequent resistance profile was against beta-lactams, quinolones, and tetracyclines (38/44); the ESBL-negative strains were resistant to aminoglycosides, quinolones, and tetracyclines (36/54). The results for *Salmonella* spp. antimicrobial susceptibility test are presented in Fig. 2.

The strains, sensitive to all antimicrobials (3/98), originated from Room 3 and represented 16% (3/19) of the total number of strains isolated from this room. The same percentage of resistance was observed for only one or two antimicrobial classes and 52% (10/19) strains were multidrug resistant. However, in Rooms 1, 2, and 4, 100% (26/26), 87% (20/23), and 93% (28/30), respectively, of the *Salmonella* spp. strains were multidrug resistant. The highest numbers of ESBL-positive strain were isolated from Room 4, corresponding to 54% (24/44) of the positive strains.

| Resistance profile* |      |       |     |     |     |     |     | No | %  |
|---------------------|------|-------|-----|-----|-----|-----|-----|----|----|
| Room                | ESBL | β-LAC | AMI | QUI | SUT | TET | POL |    |    |
| 1                   | ■    | ■     |     | ■   |     | ■   |     | 6  | 23 |
|                     | ■    | ■     | ■   | ■   |     | ■   |     | 3  | 12 |
|                     |      |       | ■   | ■   | ■   | ■   |     | 14 | 54 |
|                     |      |       |     | ■   | ■   | ■   | ■   | 2  | 8  |
| 2                   |      | ■     |     | ■   |     | ■   |     | 1  | 4  |
|                     | ■    | ■     |     | ■   |     | ■   |     | 5  | 22 |
| 3                   |      |       | ■   | ■   |     | ■   |     | 15 | 65 |
|                     | ■    | ■     |     | ■   |     | ■   |     | 5  | 26 |
|                     | ■    | ■     | ■   | ■   |     | ■   |     | 1  | 5  |
| 4                   |      |       | ■   | ■   |     | ■   |     | 4  | 21 |
|                     | ■    | ■     |     | ■   |     | ■   |     | 22 | 73 |
|                     | ■    | ■     | ■   | ■   |     | ■   |     | 1  | 3  |
|                     | ■    | ■     | ■   | ■   |     | ■   | ■   | 1  | 3  |
|                     |      |       | ■   | ■   |     | ■   |     | 3  | 10 |
|                     |      | ■     |     | ■   |     | ■   |     | 1  | 3  |

**Fig. 1 – Resistance profile of multidrug resistant *Salmonella* spp. strains as per ESBL analysis and cutting room of origin. \* B-LAC, B-lactams; AMI, aminoglycosides; QUI, quinolones; SUT, sulfamethoxazole/trimethoprim; TET, tetracyclines; POL, polymyxin.**

## Discussion


Recently, incidence of antimicrobial resistance in *Salmonella* spp. isolated from foods of animal origin, especially poultry products, has increased.<sup>27–29</sup> In this study, all strains were sensitive to ciprofloxacin and 95% of them were resistant to nalidixic acid (Fig. 2). Hamidiam et al.<sup>30</sup> suggested that the low in vitro resistance to ciprofloxacin may be due to a mutation in the *gyrA* gene and that in vitro resistance to nalidixic acid may be used to detect the actual level of resistance to ciprofloxacin. The CLSI<sup>22</sup> recommends that resistance to this class of antimicrobials should be considered as collective, that is, resistance to one drug implies that the microorganism is resistant to the whole class. This information is of great importance because fluoroquinolones are considered as the drug of first choice for the treatment of infections caused by *Salmonella* spp. in human.<sup>31</sup>

High levels of resistance were also observed against tetracycline (Fig. 2). Worldwide incidence of resistance in *Salmonella* spp. isolated from the poultry production chain is variable with percentages ranging from 96.6% to 21.8%.<sup>32–34</sup> In Brazil, Oliveira et al.<sup>35</sup> reported low resistance indexes in *Salmonella* Enteritidis isolated from humans, poultry carcasses, poultry-related samples, and food items involved in food borne disease outbreaks in the southern region of the country.

Additionally, 97% of the strains tested were sensitive to chloramphenicol (Fig. 2), which is one of the first drugs used in veterinary medicine and which has been banned from animal production in Brazil since 1998.<sup>36</sup> The use of tetracycline as a growth promoter in poultry production is also prohibited in Brazil.<sup>37</sup>

All strains were sensitive to the carbapenems tested; this is an important finding because carbapenems are the drugs of first choice in the treatment of ESBL-producing microorganisms.<sup>38</sup> ESBL production was detected in 45% (44/98) of the strains. These ESBL-positive strains were also multidrug resistant. Clemente et al.<sup>17</sup> analyzed 1120 isolates of *Salmonella* spp. from food items of animal origin and found only five ESBL-producing strains. However, they used a methodology that was different from the present one. Nogueira-Miranda et al.<sup>10</sup> compared six methodologies for the detection of ESBL in *Enterobacter* spp. and concluded that the double disk diffusion test showed sensitivity of 89.2% and specificity of 100% for this species. Due to the absence of a standard methodology approved by any of the international committees for the evaluation of *Salmonella* spp., ESBL production may result in underestimation of the occurrence of this phenotype. It is also difficult to compare different studies. The phenotypic confirmatory tests are highly sensitive and specific as compared to the genotypic confirmatory tests.<sup>39</sup> This study was aimed to screen ESBL producing organisms. Further research is required for the genotypic characterization of ESBL-producing *Salmonella* spp. found in broiler processing plants.

In conclusion, the present study demonstrated multidrug resistance in 86% and ESBL activity in 45% of the *Salmonella* spp. isolated from the studied broiler processing plants. These results should be taken as a precautionary warning for the



**Fig. 2** – Percentages recorded for the antimicrobial susceptibility test of *Salmonella* spp. strains isolated from cutting rooms of broiler processing plants. AMP, ampicillin; CFC, cephalochlor; CTF, ceftiofur; MER, meropenem; IPM, imipenem; EST, streptomycin; TOB, tobramycin; GEN, gentamycin; AMI, amikacin; NEO, neomycin; ENO, enrofloxacin; NAL, nalidixic acid; CIP, ciprofloxacin; SUT, sulfamethoxazole/trimethoprim; TET, tetracycline; CLO, chloramphenicol; FLF, florfenicol; POL, polymyxin B.

spread of multidrug resistant *Salmonella* spp. in broiler production industry.

### Conflicts of interest

The authors declare no conflicts of interest.

### Acknowledgment

We are grateful to Laboratório de Inspeção e Controle de Qualidade de Alimentos e Água, Universidade Federal do Paraná (UFPR) for subsidizing the purchase materials for this study.

### REFERENCES

- Miriagou V, Tassios PT, Legakis NJ, Tzouveleakis LS. Expanded-spectrum cephalosporin resistance in non-typhoid *Salmonella*. *Int J Antimicrob Agents*. 2004;23:547–555.
- Greig JD, Ravel A. Analysis of foodborne outbreak data reported internationally for source attribution. *Int J Food Microbiol*. 2009;130:77–87.
- Berrang ME, Bailey JS, Altekruze SF, et al. Prevalence, serotype, and antimicrobial resistance of *Salmonella* on broiler carcasses postpick and postchill in 20 U.S. processing plants. *J Food Prot*. 2009;72:1610–1615.
- Rasschaert G, Houf K, Godard C, Wildemaue C, Pastuszczyk-Frak M, De Zutter L. Contamination of carcasses with *Salmonella* during poultry slaughter. *J Food Prot*. 2008;71:146–152.
- Rasschaert G, Houf K, De Zutter L. Impact of the slaughter line contamination on the presence of *Salmonella* on broiler carcasses. *J Appl Microbiol*. 2007;103:333–341.
- Threlfall EJ. Antimicrobial drug resistance in *Salmonella*: problems and perspectives in food- and water-borne infections. *FEMS Microbiol Rev*. 2002;26:141–148.
- Li XZ, Mehrotra M, Ghimire S, Adewoye L. Beta-lactam resistance and beta-lactamases in bacteria of animal origin. *Vet Microbiol*. 2007;121:197–214.
- de Jong A, Smet A, Ludwig C, et al. Antimicrobial susceptibility of *Salmonella* isolates from healthy pigs and chickens (2008–2011). *Vet Microbiol*. 2014;171:298–306.
- Livermore DM. Defining an extended-spectrum beta-lactamase. *Clin Microbiol Infect*. 2008;14(suppl 1):3–10.
- Nogueira-Miranda KS, Palmeiro JK, Conte D, et al. Detection of extended-spectrum  $\beta$ -lactamase in *Enterobacter* spp. – evaluation of six phenotypic tests. *Microb Drug Resist*. 2012;18:66–70.
- Nogueira KS, Paganini MC, Conte A, et al. Emergence of extended-spectrum  $\beta$ -lactamase producing *Enterobacter* spp. in patients with bacteremia in a tertiary hospital in southern Brazil. *Enferm Infecç Microbiol Clin*. 2014;32:87–92.
- Cohen Stuart J, van den Munckhof T, Voets G, Scharringa J, Fluit A, Hall MLV. Comparison of ESBL contamination in organic and conventional retail chicken meat. *Int J Food Microbiol*. 2012;154:212–214.
- Ryu SH, Lee JH, Park SH, et al. Antimicrobial resistance profiles among *Escherichia coli* strains isolated from commercial and cooked foods. *Int J Food Microbiol*. 2012;159:263–266.
- Ojer-Usoz E, González D, Vitas AI, et al. Prevalence of extended-spectrum  $\beta$ -lactamase-producing



- Enterobacteriaceae* in meat products sold in Navarra, Spain. *Meat Sci.* 2013;93:316–321.
15. Clemente L, Correia I, Themudo P, Neto I, Caniça M, Bernardo F. Antimicrobial susceptibility of *Salmonella enterica* isolates from healthy breeder and broiler flocks in Portugal. *Vet J.* 2014;200:276–281.
  16. Jiang HX, Song L, Liu J, et al. Multiple transmissible genes encoding fluoroquinolone and third-generation cephalosporin resistance co-located in non-typhoidal *Salmonella* isolated from food-producing animals in China. *Int J Antimicrob Agents.* 2014;43:242–247.
  17. Clemente L, Manageiro V, Ferreira E, et al. Occurrence of extended-spectrum  $\beta$ -lactamases among isolates of *Salmonella enterica* subsp. *enterica* from food-producing animals and food products, in Portugal. *Int J Food Microbiol.* 2013;167:221–228.
  18. Egervärn M, Börjesson S, Byfors S, et al. *Escherichia coli* with extended-spectrum beta-lactamases or transferable AmpC beta-lactamases and *Salmonella* on meat imported into Sweden. *Int J Food Microbiol.* 2014;171:8–14.
  19. Andrews W, Hammack T. *Salmonella*. In: *Bacteriological Analytical Manual [s.l.]*. U.S. Food and Drug Administration; 2007.
  20. de Almeida MV, Silva A Jr, Nero LA. Evaluation of target sequences for the polymerase chain reaction-based detection of *Salmonella* in artificially contaminated beef. *Foodborne Pathog Dis.* 2014;11:111–118.
  21. CLSI. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals. Approved Standard.* CLSI Document M31-A3. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
  22. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing. 23rd Informational Supplement.* CLSI Document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
  23. Ngoi ST, Thong KL. Molecular characterization showed limited genetic diversity among *Salmonella Enteritidis* isolated from humans and animals in Malaysia. *Diagn Microbiol Infect Dis.* 2013;77:304–311.
  24. Pitout JDD, Reisbig MD, Venter EC, Church DL, Hanson ND. Modification of the double-disk test for detection of enterobacteriaceae producing extended-spectrum and AmpC  $\beta$ -lactamases. *J Clin Microbiol.* 2003;41:3933–3935.
  25. Sousa MA Jr, Ferreira EV, Conceição GC. Betalactamase de espectro estendido (ESBL): um importante mecanismo de resistência bacteriana e sua detecção no laboratório clínico. *NewsLab.* 2004;63:152–174.
  26. EUCAST. *European Committee on Antimicrobial Susceptibility Testing Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance.* European Society of Clinical Microbiology and Infectious Diseases: Sweden; 2013.
  27. Antunes P, Réu C, Sousa JC, Peixe L, Pestana N. Incidence of *Salmonella* from poultry products and their susceptibility to antimicrobial agents. *Int J Food Microbiol.* 2003;82:97–103.
  28. Hur J, Kim JH, Park JH, Lee YJ, Lee JH. Molecular and virulence characteristics of multi-drug resistant *Salmonella Enteritidis* strains isolated from poultry. *Vet J.* 2011;189:306–311.
  29. Bacci C, Boni E, Alpigiani I, Lanzoni E, Bonardi S, Brindani F. Phenotypic and genotypic features of antibiotic resistance in *Salmonella enterica* isolated from chicken meat and chicken and quail carcasses. *Int J Food Microbiol.* 2012;160:16–23.
  30. Hamidian M, Tajbakhsh M, Tohidpour A, Rahbar M, Zali MR, Walther-Rasmussen J. Detection of novel gyrA mutations in nalidixic acid-resistant isolates of *Salmonella enterica* from patients with diarrhoea. *Int J Antimicrob Agents.* 2011;37:360–364.
  31. Pokharel BM, Koirala J, Dahal RK, Mishra SK, Khadga PK, Tuladhar NR. Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing *Salmonella enterica* (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. *Int J Infect Dis.* 2006;10:434–438.
  32. Manie T, Khan S, Brözel VS, Veith WJ, Gouws PA. Antimicrobial resistance of bacteria isolated from slaughtered and retail chickens in South Africa. *Lett Appl Microbiol.* 1998;26:253–258.
  33. Carramiñana JJ, Rota C, Agustín I, Herrera A. High prevalence of multiple resistance to antibiotics in *Salmonella serovars* isolated from a poultry slaughterhouse in Spain. *Vet Microbiol.* 2004;104:133–139.
  34. Thai TH, Hirai T, Lan NT, Yamaguchi R. Antibiotic resistance profiles of *Salmonella serovars* isolated from retail pork and chicken meat in North Vietnam. *Int J Food Microbiol.* 2012;156:147–151.
  35. Dias de Oliveira S, Siqueira Flores F, dos Santos LR, Brandelli A. Antimicrobial resistance in *Salmonella enteritidis* strains isolated from broiler carcasses, food, human and poultry-related samples. *Int J Food Microbiol.* 2005;97:297–305.
  36. Brasil. Portaria n. 448, de 10 de setembro de 1998. Dispõe sobre a proibição de fabricação, importação, comercialização e o emprego de preparações farmacêuticas de uso veterinário, de rações, e de aditivos alimentares que especifica e revoga a portaria que menciona. Ministério da Agricultura e Abastecimento, Brasília; 1998.
  37. Brasil. Portaria n° 159, de 23 de junho de 1992. Dispõe sobre a proibição do uso de clortetraciclina, oxitetraciclina e penicilina como promotores de crescimento. Ministério da Agricultura e Abastecimento, Brasília.
  38. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. *Drugs.* 2007;67:1027–1052.
  39. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev.* 2005;18:657–686.